GLP1-RA, Kidney Disease
The researchers urged physicians to be vigilant for signs of pancreatitis and to monitor kidney function among people taking GLP-1 medications. Kidney problems can occur without symptoms ...
Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than ...
as well as kidney issues. On the flip side, recent studies show that GLP-1 medications may decrease a person’s risk for cardiovascular disease and dementia. Now, a new study recently published ...
GLP-1 agonists also were tied to 12% reduced risk for acute kidney injury and 3% lower risk ... and a stabilizing effect on endothelial function, which may be driving cardiovascular benefits ...
Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...
Previous studies have found that SGLT2 inhibitors appear to lower HbA1c less in patients with worse kidney function.” “GLP-1 agonists appear to be less affected by this interaction,” he added.
As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback